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Abstract
The pregnane X receptor (PXR), a member of the nuclear receptor superfamily, regulates the 
expression of drug-metabolizing enzymes in a ligand-dependent manner. The conventional view 
of nuclear receptor action is that ligand binding enhances the receptor’s affinity for coactivator 
proteins, while decreasing its affinity for corepressors. To date, however, no known rigorous 
biophysical studies have been conducted to investigate the interaction among PXR, its 
coregulators, and ligands. In this work, steady-state total internal reflection fluorescence 
microscopy (TIRFM) and total internal reflection with fluorescence recovery after photobleaching 
were used to measure the thermodynamics and kinetics of the interaction between the PXR ligand 
binding domain and a peptide fragment of the steroid receptor coactivator-1 (SRC-1) in the 
presence and absence of the established PXR agonist, rifampicin. Equilibrium dissociation and 
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dissociation rate constants of ~5 μM and ~2 s−1, respectively, were obtained in the presence and 
absence of rifampicin, indicating that the ligand does not enhance the affinity of the PXR and 
SRC-1 fragments. Additionally, TIRFM was used to examine the interaction between PXR and a 
peptide fragment of the corepressor protein, the silencing mediator for retinoid and thyroid 
receptors (SMRT). An equilibrium dissociation constant of ~70 μM was obtained for SMRT in the 
presence and absence of rifampicin. These results strongly suggest that the mechanism of ligand-
dependent activation in PXR differs significantly from that seen in many other nuclear receptors.
The nuclear receptor superfamily consists of structurally related proteins that regulate the 
transcription of target genes in a ligand-dependent manner. Nuclear receptors, which include 
the estrogen, androgen, thyroid, and vitamin D receptors, regulate a variety of biological 
processes, including reproduction, development, metabolism, and energy homeostasis, in 
response to various hydrophobic ligands. The pregnane X receptor (PXR), a member of the 
nuclear receptor superfamily, protects the body from potentially toxic compounds by 
regulating the expression of proteins that metabolize and excrete these compounds from 
cells.1
PXR binds promiscuously to a wide variety of compounds, including naturally occurring 
steroids, hormones, and bile acids, as well as exogenous ligands like insecticides, herbal 
extracts, and pharmaceutical products.1 PXR has been implicated in adverse drug–drug 
interactions, whereupon being activated by a drug, PXR promotes the expression of 
enzymes that metabolize the activating drug, as well as other co-administered therapeutics. 
Such adverse effects have been observed with hyperforin, a constituent in the herbal product 
St. John’s Wort, and rifampicin, an antibiotic, both of which have been shown to bind and 
activate PXR.2–7
PXR works in concert with its heterodimerization partner, the retinoid X receptor (RXR), to 
bind promoter regions of target genes and coactivators like the steroid receptor coactivator-1 
(SRC-1). The PXR–RXR–coactivator–DNA complex then recruits and directs downstream 
members of the transcription machinery.5,6 Crystal structures of several nuclear receptor 
ligand binding domains (LBDs) in the apo and ligand-bound states indicate that in the 
presence of an agonist, an α-helix at the C-terminus called activation function-2 (AF-2) 
undergoes a conformational change that allows nuclear receptors to bind coactivators.8–11 
Specifically, in the active conformation, nuclear receptors form a critical charge clamp with 
conserved LXXLL motifs (where X is any amino acid) found in coactivators.11,12
In the absence of ligand, the transcriptional activity of nuclear receptors is, in part, 
downregulated by the action of corepressor proteins. The nuclear receptor corepressor 
known as the silencing mediator of retinoid and thyroid receptors (SMRT) has been shown 
to repress both the basal and ligand-induced transcriptional activity of PXR.13–15 
Corepressors bind nuclear receptors via receptor interaction domains containing conserved 
LXXXIXXXL motifs and recruit proteins, including histone deacetylases, that suppress 
transcription. A crystal structure of a nuclear receptor (peroxisome proliferator-activated 
receptor-α) LBD in complex with a peptide fragment of SMRT shows that AF-2 is displaced 
from its active conformation upon corepressor binding.16 Corepressors thereby inhibit the 
transcriptional activity of nuclear receptors by preventing the recruitment of coactivators.
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This paper provides a biophysical assessment of the interaction between PXR-LBD and 
peptides derived from the coactivator, SRC-1, and the corepressor, SMRT, in the presence 
and absence of the well-established PXR agonist, rifampicin. For the first time, we report 
equilibrium constants for PXR-LBD–coregulator interactions and dissociation rate constants 
for the PXR-LBD–SRC-1 interaction measured by steady-state total internal reflection 
fluorescence microscopy (TIRFM)17–20 and total internal reflection with fluorescence 
recovery after photobleaching (TIR-FRAP),21–23 respectively. This quantitative information 
strongly suggests that the mode of ligand-dependent activation of PXR differs from that of 
most other nuclear receptors studied to date.
MATERIALS AND METHODS
PXR-LBD Cloning, Expression, Purification, and Labeling
The LBD of human PXR (residues 130–434) was expressed as a fusion protein with an 
amino-terminal AviTag and His6 tag (for purification). The AviTag allows for the specific 
biotinylation of the tagged protein by the Escherichia coli enzyme BirA. A codon-optimized 
version of the PXR-LBD gene (GenScript USA, Piscataway, NJ) was cloned into pET21c(+) 
between NdeI and HindIII, along with an N-terminal AviTag sequence (Avidity, Denver, 
CO) followed by a His6 sequence. With this insert, two stop codons were introduced 
upstream of the C-terminal His6 tag normally found in pET21c(+). PXR-LBD was 
coexpressed with an 88-amino acid fragment of SRC-1 to enhance PXR stability. The 
SRC-1 fragment (residues 623–710), along with the T7 promoter, had been previously 
inserted into the pACYC184 vector at the HindIII and BamHI sites.24,25 The pET21c-
AviTag-His6-PXR-LBD and pACYC184-SRC-1 plasmids were cotransformed into the 
BL21 DE3 Gold E. coli strain.
Terrific Broth (3 L) supplemented with ampicillin (100 μg/mL) and chloramphenicol (35 
μg/mL) was inoculated with an overnight culture (0.5% innoculant). Cells were grown at 37 
°C to an OD600 of ~2.7 and induced with 0.1 mM isopropyl β-D-thiogalactopyranoside at 18 
°C for ~16 h. Cells were harvested by centrifugation (30 min at 3500g and 4 °C) and stored 
at −80 °C. Cell pellets (~25 g) were resuspended in 125 mL of buffer A [20 mM Tris (pH 
7.9), 250 mM NaCl, 5% glycerol, 20 mM imidazole, and 0.1 mM tris(2-
carboxyethyl)phosphine (TCEP) (Soltec Ventures, Beverly, MA)] supplemented with three 
protease inhibitor tablets (complete, EDTA-free; Roche Diagnostics, Mannheim, Germany) 
and DNase (50 μg/mL; Worthington Biochemical Corp., Lakewood, NJ) and then subjected 
to Dounce homogenization. Cell homogenates were tip sonicated on ice, and the cell lysates 
were then clarified by centrifugation (45 min at 27000g and 4 °C). The clarified cell lysates 
were incubated with 750 μL of His-Select Ni resin (Sigma-Aldrich, St. Louis, MO) 
equilibrated in buffer A for 1 h at 4 °C. The resin was subsequently washed with 125 mL of 
buffer B [20 mM Tris (pH 7.9), 500 mM NaCl, 5% glycerol, and 20 mM imidazole]. PXR-
LBD was eluted using six aliquots of 1 mL each of buffer C [20 mM Tris (pH 7.9), 250 mM 
NaCl, 5% glycerol, 2 mM TCEP, and 300 mM imidazole]. Protein fractions were combined 
and dialyzed against buffer D [20 mM Tris (pH 7.9), 250 mM NaCl, 5% glycerol, and 2 mM 
TCEP] at 4 °C. Thereafter, PXR-LBD was quickly frozen in liquid N2 and stored at −80 °C 
in 1 mL aliquots at a concentration of 0.1 mg/mL.
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The AviTag-His6-PXR-LBD fusion protein, henceforth termed PXR-LBD, has a molecular 
mass of 38750 Da with an extinction coefficient at 280 nm of 34080 M−1 cm−1.26 Protein 
concentrations were measured by using both the absorbance at 280 nm and the Bradford 
assay (Bio-Rad Laboratories, Hercules, CA). Sodium dodecyl sulfate–polyacrylamide gel 
electrophoresis with Coomassie Brilliant Blue and silver stains indicated that the primary 
band was at the molecular mass expected for PXR-LBD and impurities were negligible. 
Silver-stained gels showed no bands close to or at 10 kDa, suggesting that the coexpressed, 
9.8 kDa SRC-1 fragment was removed during PXR purification. Western blots with anti-
biotin antibodies conjugated to horseradish peroxidase (Cell Signaling Technology, Beverly, 
MA) were used to confirm in vivo biotinylation. The molar ratio of biotin to PXR-LBD, as 
estimated by using Pierce Biotin Quantitation Kit (Thermo Scientific, Rockford, IL), ranged 
from 0.7 to 1.3, indicating that a majority of the protein was biotinylated.
For some control measurements, PXR-LBD was fluorescently labeled with an amine 
reactive dye, Alexa Fluor 488 5-TFP (Invitrogen, Carlsbad, CA). Briefly, PXR-LBD that 
eluted from the Ni affinity column during purification was concentrated to ~1.5 mg/mL and 
incubated with a 10–15-fold molar excess of the dye for 2 h at 4 °C with continuous, gentle 
stirring. Free dye was removed by passing the solution through an anion exchange column 
(4 mL) constructed from Dowex 1X8 resin (Acros Organics, Morris Plains, NJ) and 
equilibrated in 10 mM sodium phosphate and 5% glycerol (pH 5.3). Protein was 
immediately dialyzed against buffer D. The molar ratio of dye to protein, as determined by 
the relative absorptivities at 280 and 494 nm, was approximately 0.3. As before, protein 
aliquots were frozen in liquid N2 and stored at −80 °C.
A ligand-bound mimic of PXR-LBD was made by mutating two residues in the ligand 
binding pocket to tryptophans: S247W and C284W.27 The mutations were made 
sequentially using the QuikChange-II Site-Directed Mutagenesis Kit (Stratagene, La Jolla, 
CA) according to the manufacturer’s protocol. The following primers (with mutated 
nucleotides underlined) were used for the S247W mutation: forward, 5′-
gcacatggcagatatgTGGacctatatgttcaaaggc-3′; and reverse, 5′-
gcctttgaacatataggtCCAcatatctgccatgtgc-3′. For the C284W mutation, the following primers 
were used: forward, 5′-gcagcgtttgaactgTTGcagctgcgtttcaac-3′; and reverse, 5′-
gttgaaacgcagctgCCAcagttcaaacgctgc-3′. Mutations were generated using the pET21c-
AviTag-His6-PXR-LBD plasmid as a template and confirmed by sequencing. PXR-LBD 
(S247W/C284W) was expressed and purified as described above for wild-type (WT) PXR-
LBD.
Coregulator Peptide Synthesis and Fluorescence Labeling
A 25-amino acid fragment of SRC-1 (676-CPSSWSSLTERHKILHRLLQEGSPS-700) was 
synthesized at the University of North Carolina Microprotein Sequencing and Peptide 
Synthesis Facility. Residue 680 was mutated from histidine to tryptophan (H680W) to 
facilitate peptide quantification. The average and monoisotopic molecular masses of the 
peptide are 2849.18 and 2847.44 Da, respectively. The molar absorptivity of the peptide at 
280 nm is 5810 M−1 cm−1. The N-terminal cysteine residue was fluorescently labeled with a 
thiol reactive dye, fluorescein C5 maleimide (AnaSpec, Fremont, CA). Briefly, peptide (5 
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mg, 1.8 μM), a 2-fold molar excess of TCEP, and a 4-fold molar excess of dye were 
combined in 50 mM sodium phosphate (pH 7.6). The reaction mixture was stirred under 
argon for ~5 h at room temperature and for an additional ~19 h at 4 °C. Free dye was 
removed by passing the mixture through an anion exchange column (4 mL) constructed 
from Dowex 1X8 resin, both equilibrated and washed with 50 mM sodium acetate (pH 5.0). 
The peptide was further purified using high-performance liquid chromatography (HPLC) to 
remove salts. Briefly, a 0 to 40% gradient of solvent B (95% acetonitrile, 5% water, and 
0.1% trifluoroacetic acid) in solvent A (95% water, 5% acetonitrile, and 0.1% trifluoroacetic 
acid) was generated on an Atlantis dC18 (10 mm × 100 mm) column and Waters HPLC with 
Delta 600 pumps (Waters Corp., Milford, MA) at a flow rate of 4 mL/min. Peptide fractions 
were combined, lyophilized, and stored at −20 °C. Peptide labeling was confirmed by mass 
spectrometry. The molar ratio of fluorescein to peptide was determined by using the 
absorptivities at 280 and 494 nm. Labeling ratios ranged from 0.35 to 0.50. The 
fluorescently labeled SRC-1 peptide is henceforth denoted as F-SRC-1. Labeled and 
unlabeled peptides were mixed to yield an overall F-SRC-1 labeling ratio of 0.10, unless 
otherwise indicated.
Peptide fragments of SMRT (2337-TNMGLEAIIRKALMGKYDQWEE-2358) and of a 
second corepressor protein, called the nuclear receptor corepressor (NCoR, 2251-
GHSFADPASNLGLEDIIRKALMGSF-2275), were synthesized at the University of North 
Carolina Microprotein Sequencing and Peptide Synthesis Facility. The concentration of 
SMRT was determined spectrophotometrically using the peptide’s extinction coefficient at 
280 nm, 6970 M−1 cm−1. The concentration of NCoR was determined by measuring the 
mass of the lyophilized peptide.
Other Reagents
D-Biotin (Acros Organics, Morris Plains, NJ), unreactive fluorescein reference standard 
(Invitrogen, Eugene, OR), NeutrAvidin (Thermo Scientific, Rockford, IL), ovalbumin 
(Sigma-Aldrich), and rifampicin (Fisher Scientific, Fairlawn, NJ) were obtained 
commercially. Concentrations for the last four reagents were determined 
spectrophotometrically by using the following extinction coefficients: fluorescein, 68000 
M−1 cm−1 at 494 nm; NeutrAvidin, 99600 M−1 cm−1 at 280 nm; ovalbumin, 31500 M−1 
cm−1 at 280 nm; and rifampicin, 26400 M−1 cm−1 at 334 nm. For some control 
measurements, NeutrAvidin was fluorescently labeled with Alexa Fluor 488 5-TFP 
(Invitrogen). NeutrAvidin (2 mg/mL) and a 5-fold molar excess of dye were dissolved in 
100 mM sodium phosphate (pH 8.0). The mixture was incubated at 25 °C for 1 h with 
continuous, gentle stirring. Thereafter, free dye was removed by passing the mixture through 
an anion exchange column (4 mL) constructed from Dowex 1X8 resin and equilibrated in 
100 mM sodium acetate with 500 mM NaCl (pH 4.0). Labeled protein was dialyzed against 
buffer D. The molar ratio of dye to protein, determined spectrophotometrically, was 
approximately 0.7.
Sample Preparation
Immediately before use, all protein samples were centrifuged (~100000g for 30 min; 
Airfuge; Beckman-Coulter, Fullerton, CA) to remove possible aggregates. NeutrAvidin and 
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ovalbumin were filtered (0.1 μm, 13 mm, Anatop; Whatman, GE Healthcare, Piscataway, 
NJ) following centrifugation. Microscope (3 in. × 1 in. × 1 mm; Gold Seal Products, 
Porstmouth, NH) and fused silica (0.25 in. × 1 in. × 1 mm; Quartz Scientific, Fairport 
Harbor, OH) slides were cleaned by being boiled in ICN detergent (MP Biomedicals, Solon, 
OH) diluted in water, sonicated in a bath, rinsed extensively in deionized water, and dried at 
120 °C. Immediately prior to the collection of data, the substrates were further cleaned in an 
argon ion plasma cleaner (PDC-3XG, Harrick Scientific, Ossining, NY) for 15 min at room 
temperature. Fused silica slides were mounted on microscope slides using double-sided, 
0.13 mm thick, tape (part no. 021200-64988, 3M Corp., St. Paul, MN). A NeutrAvidin/
ovalbumin mixture (0.5 and 0.1 mg/mL, respectively, in buffer D, 60 μL) was applied to the 
space between the fused silica and microscope slides. Slides were incubated at room 
temperature for 1 h, allowing the NeutrAvidin and ovalbumin to coat the surfaces of the 
substrates. Excess protein was removed by washing the inner sample chambers with buffer 
D (10 × 200 μL). NeutrAvidin- and ovalbumin-coated sample chambers were treated with 
PXR-LBD (0.1 mg/mL in buffer D, 200 μL) for 5 min at room temperature and washed with 
buffer D (10 × 200 μL) to remove excess PXR. For steady-state TIRFM and TIR-FRAP 
measurements to yield F-SRC-1–PXR-LBD equilibrium and dissociation rate constants, 
solutions (200 μL) containing F-SRC-1 and ligand in buffer D at the indicated 
concentrations were applied to the sample chambers. Immediately thereafter, samples were 
mounted onto the microscope for data collection. For competition curves to yield SMRT–
PXR-LBD equilibrium constants, solutions (200 μL) containing 5 μM F-SRC-1, rifampicin, 
and SMRT in buffer D at the indicated concentrations were applied to the sample chambers. 
SMRT was replaced with a peptide fragment of the corepressor, NCoR, in some 
measurements.
Fluorescence Microscopy
Steady-state TIRFM and TIR-FRAP were conducted using the equipment described below. 
A through-prism TIRFM apparatus was used to generate evanescent illumination with an 
elliptically Gaussian spatial profile having the following 1/e2 radii: wx = 22.4 ± 0.5 μm, and 
wy = 65.0 ± 0.4 μm, respectively.28 Measurements were conducted using an argon ion laser 
(Innova 90-3, Coherent, Palo Alto, CA), an inverted microscope (Zeiss Axiovert 35, Carl 
Zeiss Inc., Thornwood, NY) with a 40×, 0.55 numerical aperture, long working distance 
objective (Nikon Instruments Inc., Nelville, NY), and an avalanche photodiode (SPCM-
AQ-151, EG&G Optoelectronics, Quebec City, QC) detector. An in-house LabVIEW 
program and DAQ board (PCI-MIO-16XE-50, National Instruments, Austin, TX) were used 
to control the instruments. Fluorescence was excited at 488 nm and detected through a 
dichroic mirror and barrier filter, at room temperature. All data were fitted in SigmaPlot 11.0 
(Systat Software Inc., San Jose, CA).
Steady-State Total Internal Reflection Fluorescence Microscopy
Steady-state TIRFM17–19 was used to measure equilibrium dissociation constants for the 
interaction between the F-SRC-1–PXR-LBD complex and the SMRT–PXR-LBD complex 
under different conditions, including different rifampicin concentrations. All samples were 
evanescently illuminated, and the surface-associated fluorescence was measured using a 
personal computer-based correlator board (ALV-5000/E, ALV, Langen, Germany). 
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Fluorescence intensities, averaged over 10 s, were measured at eight distinct sites on a given 
sample.
To characterize the F-SRC-1–PXR-LBD interaction, the surface-associated fluorescence of 
samples was measured as a function of the F-SRC-1 concentration in solution. The 
measured surface-associated fluorescence was assumed to be proportional to the average 
density of fluorescent molecules bound to surface binding sites (PXR-LBD), as well as the 
average density of such molecules diffusing in the evanescent wave. To obtain the 
fluorescence associated with F-SRC-1–PXR-LBD complexes alone, fluorescence measured 
in the absence of PXR-LBD was subtracted from the total fluorescence. This background-
corrected fluorescence was plotted as a function of the F-SRC-1 concentration and fit to a 
model of single-site binding to yield an apparent equilibrium dissociation constant.
Competition curves were used to determine the equilibrium dissociation constant for the 
interaction between PXR-LBD and corepressor peptides. TIRFM was used to measure the 
surface-associated fluorescence arising from 5 μM F-SRC-1 reversibly interacting with 
surface-immobilized PXR-LBD in the presence of an increasing concentration of the 
corepressor peptide. The corepressor competed with F-SRC-1 to bind PXR-LBD, and a 
corresponding decrease in the surface-associated fluorescence was observed. The 
background, arising from fluorescence due to the diffusion of free F-SRC-1 in the 
evanescent wave, was subtracted, and the data were fit to an appropriate model (see Results) 
to obtain the equilibrium dissociation constant for the interaction between the PXR and 
corepressor fragments.
Total Internal Reflection with Fluorescence Recovery after Photobleaching
TIR-FRAP21,22,29,30 was used to measure the apparent dissociation rate constant for the F-
SRC-1–PXR-LBD interaction. In this technique, an evanescently illuminated area is 
photobleached, and the subsequent fluorescence recovery is observed as a function of time. 
Fluorescence recovery, which occurs when photobleached molecules on the surface are 
replaced by unbleached molecules from solution, is proportional to the intrinsic rate at 
which photobleached molecules dissociate from surface binding sites, in the absence of 
surface rebinding. Recovery curves were fit to an appropriate exponential model to obtain 
the off rate for the F-SRC-1–PXR-LBD interaction (see Results for more detail). TIR-FRAP 
measurements were taken using bleach pulses with intensities of 100–300 mW and 




TIRFM and related techniques specifically allow one to probe the behavior of fluorescent 
species close to or at interfaces. Therefore, we immobilized biotinylated PXR-LBD on 
NeutrAvidin-coated microscope slides via the biotin–avidin linkage. TIRFM-based 
techniques were used to examine coactivator and corepressor peptides in solution reversibly 
interacting with surface-bound PXR-LBD, in the presence and absence of rifampicin.
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It was necessary, first, to confirm that NeutrAvidin and PXR-LBD were irreversibly bound 
to the surface. To probe the surface lifetime of NeutrAvidin, fluorescently labeled 
NeutrAvidin (0.5 mg/mL) along with ovalbumin (0.1 mg/mL) was immobilized on 
microscope slides; the slides were then washed, and the surface-associated fluorescence was 
monitored for 90 min at 30 min intervals using TIRFM (data not shown). Although the 
fluorescence decreased 13 ± 3% over the first 30 min period, no further decrease was 
observed. To probe the surface lifetime of PXR-LBD, slides were coated with a mixture of 
NeutrAvidin (0.5 mg/mL) and ovalbumin (0.1 mg/mL), washed, treated with fluorescently 
labeled PXR-LBD (0.1 mg/mL), and washed, and then the surface-associated fluorescence 
was monitored for 90 min at 30 min intervals using TIRFM (data not shown). Although the 
fluorescence decreased 13 ± 3% over the 90 min period, the decrease was only 3 ± 3% after 
30 min. As all TIRFM equilibrium and TIR-FRAP kinetic measurements, for individual 
samples, were obtained within at least 30 min of the final wash, the calibrated surface 
residency times for NeutrAvidin and PXR were judged to be sufficient.
PXR-LBD was biotinylated at its N-terminus, away from the ligand binding pocket, the 
SRC-1 peptide binding site, the SMRT binding site, and AF-2,7,25 to minimize the 
possibility that biotinylation and subsequent immobilization would affect the interaction 
with ligands and coregulators. To determine whether PXR-LBD specifically bound 
NeutrAvidin during surface immobilization, fluorescently labeled PXR-LBD (F-PXR-LBD) 
was applied to NeutrAvidin-coated substrates in the presence and absence of excess (100 
μM) D-biotin. Figure 1 shows that in the presence of excess D-biotin the surface-associated 
fluorescence decreased markedly, indicating that F-PXR-LBD specifically bound 
NeutrAvidin. All subsequent measurements were conducted at a PXR-LBD concentration of 
0.1 mg/mL.
PXR has the ability to bind many types of ligands, and in the measurements reported here, 
the SRC-1 peptide was labeled with fluorescein maleimide. To ensure that fluorescein is not 
a PXR ligand, the surface-associated fluorescence as a function of the concentration of the 
unreactive fluorescein reference standard in solution was examined in the presence and 
absence of surface-bound PXR-LBD (data not shown). Data were obtained for fluorescein 
concentrations ranging up to 9 μM, above the maximum concentration of labeled F-SRC-1 
used in subsequent measurements (usually 3.5 μM). The evanescently excited fluorescence 
intensities measured in the presence and absence of PXR-LBD were identical and linear 
with the fluorescein concentration, indicating that the fluorescence arose solely from 
fluorescein in solution and that, therefore, fluorescein is not a PXR ligand.
F-SRC-1–PXR-LBD Equilibrium Dissociation Constants Measured by Steady-State TIRFM
Steady-state TIRFM was used to examine the thermodynamics of the interaction between F-
SRC-1 and PXR-LBD at different rifampicin concentrations. The surface-associated 
fluorescence arising from both F-SRC-1 bound to immobilized PXR-LBD and free F-SRC-1 
in solution that were close enough to the surface to be excited by the evanescent field, 
denoted by F(+), was measured as a function of the F-SRC-1 concentration in solution. Also 
measured was the fluorescence solely from F-SRC-1 in solution, denoted by F(−), obtained 
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from samples not treated with PXR-LBD. The difference, which gives a measure of the 
density of specifically bound F-SRC-1, is denoted by F(+)–F(−). These three quantities are, 
in the simplest case, given by
(1)
where Q is a proportionality constant, S is the surface density of PXR-LBD, A is the solution 
concentration of F-SRC-1 (only 10 or 30% of which is actually labeled), Kd is the 
equilibrium dissociation constant describing the reversible association of F-SRC-1 with 
PXR-LBD, d is the depth of the evanescent field, and b is a constant background signal.
For a given, matched set of measured F(+) and F(−) intensities (see Figure 2A), the 
following procedure was used to find the best-fit value of the equilibrium dissociation 
constant, Kd. The experimentally determined values of F(−) were fit to the second 
expression in eq 1 with A as the abscissa and Qd and b as free parameters. The best-fit 
values of Qd and b were used to calculate theoretical values for F(−) for the values of A at 
which F(+) intensities had been obtained. The theoretical values of F(−) were subtracted 
from the experimental values of F(+) (see Figure 2B). The fluorescence differences were 
then fit to the third expression in eq 1 with QS and Kd as free parameters. A representative 
binding curve from a single trial is shown in Figure 2.
Equilibrium dissociation constants pertaining to the F-SRC-1–PXR-LBD interaction, 
obtained at rifampicin concentrations that ranged from 0 to 100 μM, are listed in Table 1. As 
the reported equilibrium dissociation constants for rifampicin and PXR-LBD are ≤10 
μM,31,32 at 100 μM rifampicin one would expect most (≥91%) of the surface-immobilized 
PXR-LBD to be in the ligand-bound state. The measured dissociation constants are within 
error of each other, indicating that rifampicin does not affect the affinity of the receptor for 
F-SRC-1. To verify these results, binding curves for which the surface-associated 
fluorescence was measured as a function of the rifampicin concentration, ranging from 0 to 
100 μM, were obtained (data not shown). In these measurements, the F-SRC-1 concentration 
was kept constant at 2.5 μM. The surface-associated fluorescence did not change, within 
experimental uncertainty, with rifampicin concentration, supporting our previous finding 
that rifampicin does not affect the interaction between PXR-LBD and the SRC-1 fragment. 
A PXR-LBD mutant (S247W/C284W), which was made to mimic a ligand-bound state of 
the receptor via the introduction of bulky tryptophan residues into the ligand binding 
pocket,27 served as a control. Many such mutants have been shown to constitutively recruit 
the coactivator and promote the transcription of reporter genes in a ligand-independent 
manner.7,27 These measurements indicate that the F-SRC-1 peptide interacts with PXR-LBD 
as though it is ligand-bound, even in the absence of rifampicin (Table 1). Additional 
measurements were taken with 5 mM TCEP or F-SRC-1 with 30% labeling, as opposed to 2 
mM TCEP and 10% labeling for all other curves (Table 1). Equilibrium constants obtained 
at 5 mM TCEP were within error of the Kd values obtained at 2 mM TCEP (10% labeling). 
This result indicates that 2 mM TCEP was sufficient to prevent significant dimerization of 
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unlabeled SRC-1 molecules via the formation of disulfide bonds and to maintain cysteine 
residues in PXR-LBD in their reduced state, as they would be in vivo. Equilibrium constants 
obtained using F-SRC-1 with 30% labeling were within error of those obtained using 
coactivator with 10% labeling (2 mM TCEP), indicating that the fluorescein tag does not 
significantly interfere with PXR-LBD–SRC-1 binding.
The density, S, of PXR-LBD at the surface was experimentally determined by using the 
best-fit values of QS (the saturating fluorescence in the binding isotherm) and Qd (the slope 
of the background), and an estimated d value of ≈85 nm for our system.33 The density of 
PXR-LBD at the surface served as an internal control, as the values of S should be on the 
same order of magnitude for all binding curves and within error of each other for 
measurements conducted with a single batch of PXR. The densities ranged from 1 to 7 × 103 
molecules/μm2, with an average of (4 ± 2) × 103 molecules/μm2. For measurements taken 
using the same batch of PXR, the S values, as returned by the fitting program, were always 
within error of each other.
F-SRC-1–PXR-LBD Dissociation Rate Constants Measured by TIR-FRAP
TIR-FRAP was employed to examine the kinetics of the interaction between F-SRC-1 and 
PXR-LBD at 0, 10, and 100 μM rifampicin. In conducting these measurements, we 
monitored the surface-associated fluorescence generated by TIR illumination before and 
after a short, intense bleach pulse. Once an evanescently illuminated area is photobleached, 
the fluorescence recovers as surface-bound, photobleached molecules dissociate and are 
replaced by unbleached molecules in solution. The rate of this recovery reflects the rate at 
which photobleached molecules dissociate from surface binding sites.22,29 In the absence of 
surface rebinding, the temporal shape of the recovery curve is predicted to be a single 
exponential with a rate equal to the intrinsic off rate.34
Figure 3 shows two representative fluorescence recovery curves for 1.25 μM (Figure 3A) 
and 20 μM (Figure 3B) F-SRC-1 interacting with PXR-LBD in the absence of rifampicin. 
The curves were obtained using a 300 mW, 50 ms bleach pulse, and fluorescence was 
measured for 30 s after photobleaching. As shown, fluorescence recovery was rapid and 
essentially complete after 30 s.
To confirm that F-SRC-1 was indeed highly reversibly interacting with immobilized PXR-
LBD, we measured the surface-associated fluorescence following the application of F-
SRC-1 and immediately after washing with 2 mL of buffer D. The surface-associated 
fluorescence was at background levels after washing, indicating that F-SRC-1 was 
completely washed away and interacts only reversibly with PXR-LBD. This observation 
also informs one that the larger fragment of SRC-1, with which PXR-LBD is co-expressed, 
is most likely removed during the washing step following the application of PXR-LBD to 
the substrate, if not before during PXR-LBD purification [as indicated by gel electrophoresis 
(see Materials and Methods)].
In a system such as ours where F-SRC-1 reversibly interacts with surface-bound PXR-LBD, 
one would at first expect a single intrinsic dissociation rate constant. Hence, fluorescence 
recovery curves were expected to be monoexponential, with the single exponent reflecting 
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the one rate constant. However, as illustrated in Figure 3 and as previously observed for a 
variety of other systems,19,22,29 the curves are not monoexponential but are in fact better 
described by the sum of two exponentials
(2)
where f0 is the fluorescence at time zero, defined as the center of the bleach pulse. The 
weighted average of the two exponential factors, k1 and k2, can be used to determine an 
average off rate, as follows:
(3)
The fractions of the prebleach fluorescence, fp, that were bleached (β) and then recovered (μ) 
were calculated as follows:
(4)
In the TIR-FRAP measurements, the monitoring excitation intensity was sufficiently low 
that in the absence of a bleach pulse, the evanescently excited fluorescence was constant 
with no measurable decrease during the typical postbleach monitoring time of 30 s. Potential 
photoinduced artifacts arising from the intense photobleaching pulse were ruled out by three 
different types of control measurements. Here, quantitative analysis of recovery curves 
indicated no significant difference in the best-fit values of koff for (a) a 3-fold increase in the 
bleaching intensity, (b) a 2-fold increase in the bleaching time, or (c) recovery curves 
obtained following sequential bleaching of identical regions after previous fluorescence 
recovery.
TIR-FRAP recovery curves were obtained for a range of F-SRC-1 concentrations, at three 
different rifampicin concentrations. As shown in Figure 4, fluorescence recovery was 
significantly slower at lower F-SRC-1 concentrations. This observation is almost certainly 
due to the fact that at lower F-SRC-1 concentrations there is an increased density of free 
PXR-LBD on the surface. Consequently, bleached molecules that dissociate from surface 
binding sites rebind free PXR-LBD at a higher frequency, reducing the overall rate of 
fluorescence recovery and thereby the observed rate constants. The intrinsic dissociation rate 
constant was taken to be the value at which the weight-averaged off rate, koff, was 
maximized and independent of the F-SRC-1 concentration. Toward this end, average off 
rates were plotted as a function of the F-SRC-1 concentration and fit to the model shown in 
eq 529 to determine the limit of the off rate as the F-SRC-1 concentration approached 
infinity, given by :
(5)
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where koff(A) is the measured average off rate for a given value of A and C is an arbitrary 
constant. The free parameters were  and C. Intrinsic, average dissociation rate constants, 
, were obtained for the F-SRC-1–PXR-LBD interaction at 0, 10, and 100 μM rifampicin 
and found to be 2.0 ± 0.1, 2.4 ± 0.3, and 2.4 ± 0.1 s−1, respectively (Figure 4A). As with the 
thermodynamics, rifampicin does not affect the kinetics of the interaction between F-SRC-1 
and PXR-LBD.
As previously shown,35 the probability that a bleached molecule that dissociates from the 
origin at time zero has rebound at least once within the illuminated and observed area after 
the duration of the postbleach observation is
(6)
where tf is the duration of the observation time after photobleaching, wx and wy are the 1/e2 
radii of the elliptically Gaussian illuminated area, D is the diffusion coefficient of F-SRC-1 
in solution, and η describes the propensity for rebinding. The parameter η is given by
(7)
where kon is the association rate constant, obtained by computing the quotient of the 
measured dissociation rate constant and equilibrium dissociation constant. Figure 4B shows 
the values of eq 6 numerically evaluated for the following values: tf = 30 s, Kd = 4 μM, koff 
= 2 s−1, S = 3000 molecules/μm2, D = 100 μm2/s, wx = 22.4 μm, and wy = 65.0 μm. As 
shown, P is significant at the lower F-SRC-1 concentrations but becomes negligibly small 
for the higher F-SRC-1 concentrations. This information is consistent with the interpretation 
that the measured fluorescence recovery curves are significantly affected by surface 
rebinding at low F-SRC-1 concentrations but that, at the higher F-SRC-1 concentrations, the 
effects of surface rebinding are negligible and the recovery curves accurately report the 
intrinsic surface dissociation kinetics.
SMRT–PXR-LBD Equilibrium Dissociation Constants Measured by Steady-State TIRFM
SMRT–PXR-LBD equilibrium constants were obtained from competition curves in which 
SMRT was titrated against a fixed concentration of F-SRC-1 (5 μM). Steady-state TIRFM 
was used to measure the decrease in surface-associated fluorescence as increasing amounts 
of SMRT competed with a fixed concentration of F-SRC-1 to bind surface-bound PXR-
LBD. Competition curves were obtained at rifampicin concentrations of 0, 10, and 100 μM. 
Background-subtracted data were fit to eq 8 to obtain the equilibrium dissociation constant, 
Kd′, for the interaction between the corepressor and PXR-LBD.
(8)
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where Q is a proportionality constant, S is the surface density of PXR-LBD, Kd is the F-
SRC-1–PXR-LBD dissociation constant, A is the concentration of F-SRC-1, and B is the 
concentration of the corepressor. QS and Kd′ were free parameters, while Kd and A were 
fixed at 5 μM. Figure 5 shows the background-subtracted, SMRT competition curve 
obtained in the absence of ligand. Fitting the data in Figure 5 to eq 8 yielded an equilibrium 
dissociation constant of 65 ± 13 μM for the interaction between SMRT and PXR-LBD. An 
equilibrium dissociation constant of 51 ± 14 μM was obtained at 100 μM rifampicin (see 
Table 2). The fact that these values are within error of each other indicates that rifampicin 
does not alter the affinity of SMRT and PXR fragments. Competition curves were also 
obtained using a peptide fragment of another corepressor called the nuclear receptor 
corepressor (NCoR). NCoR, which has been reported not to interact with PXR,13 competed 
even more weakly with F-SRC-1 to bind surface-bound PXR-LBD [see Figure 5]. Fitting 
these data to eq 8 yielded an equilibrium constant of 200 ± 50 μM for the NCoR–PXR-LBD 
interaction in the absence of ligand. This value was within error of those obtained at 10 and 
100 μM rifampicin as shown in Table 2.
DISCUSSION
The nuclear receptor PXR plays an important role in the metabolism of endobiotic and 
xenobiotic compounds, including many pharmaceutical products, by regulating the 
expression of drug-metabolizing enzymes. The conventional view of nuclear receptor action 
is that upon binding agonists, nuclear receptors preferentially associate with coactivators, 
which in turn recruit downstream members of the transcription machinery.36 In this study, 
we investigated the interaction between the ligand binding domain of PXR and a relevant 
peptide derived from the coactivator, SRC-1, in the presence and absence of the PXR 
agonist, rifampicin. Specifically, TIRFM and TIR-FRAP were employed to examine the 
thermodynamics and kinetics of PXR-LBD interacting with a fluorescently labeled SRC-1 
peptide at different rifampicin concentrations. The equilibrium and dissociation rate 
constants for the PXR-LBD–F-SRC-1 interaction were unchanged in the presence of 
rifampicin. In the absence of ligand, the basal transcriptional activity of PXR was reported 
to be significantly reduced by the corepressor SMRT.13 Thus, the thermodynamics of the 
interaction between PXR-LBD and a peptide fragment of SMRT was also measured using 
TIRFM. Again, rifampicin had no effect on the PXR-LBD–SMRT interaction. These results 
indicate that the agonist rifampicin does not affect PXR’s affinity for (at least these two) 
coregulators.
While no known rigorous biophysical studies have been previously conducted to 
quantitatively characterize the interaction among PXR, coactivators, and ligands, the 
thermodynamics and kinetics of other nuclear receptors, particularly the steroid hormone 
receptors, interacting with coregulators and ligands have been measured. As reported above, 
apparent equilibrium and dissociation rate constants of 5 μM and 2 s−1, respectively, were 
obtained for the interaction between PXR-LBD and SRC-1 (676–700) in the presence and 
absence of rifampicin. This measured apparent equilibrium dissociation constant is at the 
weak end of the spectrum of affinities measured for nuclear receptors, many of which fall in 
the nanomolar range. Fluorescence polarization assays of full-length SRC-1 interacting with 
the full-length estrogen receptor (ER) and ER-LBD in the presence of estrogen yielded a Kd 
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of ~30 nM on both occasions.37 In the absence of ligand, no interaction was observed. 
Equilibrium constants of full-length ER and another member of the steroid receptor 
coactivator family, SRC-2, interacting in live cells have been estimated using fluorescence 
cross-correlation spectroscopy. Estimated Kd values of ~200 nM, <6 nM, and >3 μM were 
obtained for ER/SRC-2 in the apo, agonist-bound, and antagonist-bound states, 
respectively.38 Equilibrium constants of ~160 nM were obtained for the thyroid receptor 
LBD interacting with a SRC-2 fragment in the presence of thyroxin.39,40 Surface plasmon 
resonance yielded an apparent dissociation rate constant on the order of 1 × 10−2 s−1 for this 
interaction.40 However, a recent study showed that the glucocorticoid receptor (GR), like 
PXR, binds many coregulator peptides with micromolar affinity in the presence of the GR 
agonist, dexamethasone.41 Further studies have shown that another receptor, the peroxisome 
proliferator-activated receptor-γ (PPARγ), is able to bind SRC-1 in the absence of ligand 
with an equilibrium dissociation constant of 34.2 μM.42 Addition of a ligand did increase the 
affinity of PPARγ and SRC-1, and a Kd of 0.96 μM was obtained. The ability of both PXR 
and PPARγ to bind coactivators in the absence of ligand may account for their relatively 
high level of basal activity. FRET measurements have been used to examine the interaction 
between full-length, human PXR and the same 25-amino acid fragment of SRC-1 used in 
this study, as a function of the rifampicin concentration.43 While the assay did not yield 
equilibrium dissociation constants for PXR and SRC-1, it did show, contrary to our findings, 
that rifampicin slightly, but within experimental uncertainty, increased the extent of 
coactivator recruitment. We cannot yet account for this discrepancy.
The structures of LBDs are conserved among the various members of the nuclear receptor 
superfamily.44,45 Briefly, nuclear receptor LBDs consist of approximately 12 α-helices 
arranged into three layers and two to five β-strands that line a side of the ligand binding 
pocket. The ligand binding pocket exists as a cavity on one side of the LBD and is lined 
primarily by hydrophobic residues from several α-helices and β-strands. The coactivator 
binding site consists of a hydrophobic groove on the surface of the LBD, created by α-
helices 3, 4, and 12 in PXR.
Crystal structures of nuclear receptors in the apo and agonist-bound states have contributed 
to an existing molecular model of ligand-mediated interaction between nuclear receptors and 
coactivators. A crystal structure of the retinoid acid receptor in the apo state showed helix 12 
(H12), or activation function-2 (AF-2), extended away from the main body of the LBD,9 
whereas subsequent structures of ligand-bound nuclear receptor LBDs showed H12 folded 
against the body of the LBD.10,11 In this folded conformation, LBDs can bind conserved 
LXXLL motifs in coactivators via a charge clamp.11 Therefore, it is thought that H12 serves 
as the molecular switch that is modulated by ligands to promote interaction of the nuclear 
receptor with coactivators. PXR-LBD was cocrystallized with the same 25-amino acid 
fragment of SRC-1 (residues 676–700) used in this study, and the agonist SR12813.12 The 
SRC-1 fragment formed a kinked α-helix and bound to a groove on the surface of PXR-
LBD created by helices 3 (H3), 4 (H4) and 12. Two polar contacts between PXR-LBD and 
SRC-1 [K259 (H3), carbonyl oxygen of L694; E427 (H12), amine nitrogen of I689] 
constituted the charge clamp that has also been observed in other nuclear receptor–
coactivator complexes. In addition, a hydrogen bond was formed between K227 (H4) and 
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H687. This lysine residue is also conserved in other nuclear receptors, including the 
constitutive androstane, liver X, farnesoid X, and vitamin D receptors.
Crystal structures of ligand-bound nuclear receptors have helped elucidate the manner in 
which many endogenous ligands stabilize H12 in the folded or active conformation. It 
appears that a canonical π–cation interaction stabilizes H12 in the folded state in the steroid 
hormone receptors,46 which encompass the glucocorticoid, mineralcorticoid, progesterone, 
androgen, and estrogen receptors, as well as in other nuclear receptors, including the vitamin 
D, thyroid hormone, farnesoid X, and liver X receptors.47 In the non-steroid hormone 
receptors, an oxygen atom from each receptor’s endogenous ligand forms an electrostatic 
interaction with a conserved histidine in H10 or H11, which in turn makes π–cation 
interactions with a conserved tryptophan or phenylalanine in H12. In this way, ligands of 
many nuclear receptors indirectly stabilize H12 in the active conformation. However, it is 
not immediately clear from crystal structures of ligand-bound PXR-LBD how agonists 
might stabilize PXR’s H12 in the folded state. PXR ligands are structurally diverse and 
appear to lack a common chemical feature that could stabilize the active conformation. 
Furthermore, attempts to design an antagonist directed at the PXR ligand binding pocket 
have thus far failed, with many of the proposed compounds instead serving as agonists.48 It 
appears that any compound that binds PXR’s ligand binding pocket serves to activate the 
receptor. (Compounds that antagonize PXR by competing with coactivators to bind the 
receptor have been described previously.27,31) Therefore, it is likely that PXR ligands do not 
directly stabilize the active conformation and increase the receptors’s affinity for 
coactivators but instead work through an alternate mechanism to upregulate PXR activity.
A crystal structure of apo-PXR-LBD shows H12 in the active conformation, indicating that 
the folded state may be favored even in the absence of ligand.25 If the active conformation is 
energetically favored in the apo state, that fact could explain our observation that PXR-LBD 
interacts with the SRC-1 fragment in a ligand-independent manner. Furthermore, PXR has a 
high level of basal activity relative to other nuclear receptors,49 indicating that the receptor 
may be able to adopt a stable active conformation in the absence of ligand. Supporting this 
conclusion, molecular dynamics simulations on PXR have shown that the AF-2 region of the 
receptor moves as a correlated unit in the absence of ligands.50
PXR is somewhat unique because it binds promiscuously to structurally diverse ligands. In 
fact, ligands that range in molecular weight from 232 (phenobarbitol) to 823 (rifampicin) 
have been shown to activate PXR. A 60-amino acid insert found in PXR-LBD that serves to 
create a five-stranded β-sheet lining one side of the ligand binding pocket, as opposed to the 
two- or three-stranded β sheet seen in other NRs, is thought to contribute to a large, flexible 
ligand binding pocket that allows PXR to accommodate diverse ligands.25 The ligand 
binding pocket can range in volume from 1150 Å3 in the apo state25 to ~1900 Å3 with 
rifampicin bound.7 Such a large cavity in the body of this globular protein may serve to 
destabilize apo-PXR. Ligand binding may increase the stability of PXR and thereby its 
lifetime in vivo. Ligand-dependent activation of PXR might then be a consequence of the 
increased stability of the ligand-bound receptor.
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Nonetheless, studies of the interaction between PXR and SRC-1 in cells suggest that the 
interaction is enhanced in the presence of ligands. In vitro coprecipitation assays of 
bacterially expressed GST-tagged PXR-LBD and a 35S-labeled SRC-1 fragment, containing 
the coactivator’s receptor interaction domain (RID), showed a weakly enhanced interaction 
in the presence of various agonists, including rifampicin.5,51 It is worth noting that the 
corresponding interaction between a GST-tagged LBD of the estrogen receptor (ER) and 
radiolabeled SRC-1-RID was much more greatly enhanced in the presence of estradiol.51 
Mammalian two-hybrid assays have also demonstrated a ligand-dependent interaction for 
SRC-1-RID and PXR, with similar results being obtained for both full-length PXR and 
PXR-LBD.31,52 Indeed, these studies were conducted with SRC-1-RID, which contains 
three LXXLL motifs, as opposed to the 25-amino acid fragment used in this study, which 
has only one LXXLL motif, albeit the most strongly interacting one.53 However, yeast two-
hybrid assays have shown that coactivator fragments as small as eight amino acids, 
containing a single LXXLL motif, are able to interact with ER-LBD in a ligand-dependent 
manner.54 Therefore, it is unlikely that our observation that the interaction between PXR-
LBD and the SRC-1 fragment is rifampicin-independent is due to the use of a 25-amino acid 
fragment of SRC-1, as opposed to the use of a larger fragment or the full-length protein that 
is 1441 residues long. It is possible that the observed ligand dependence in the in vivo 
biochemical assays is due to an increased stability of ligand-bound PXR.
Thermal denaturation studies using circular dichroism spectropolarimetry have shown that 
ligands do stabilize PXR-LBD. Melting temperatures of 43.0 ± 0.08,12 48.4 ± 0.05,12 and 
46.5 ± 0.0555 °C were obtained for apo, SR12813-bound, and rifampicin-bound PXR-LBD, 
respectively. A complex of SRC-1 and PXR-LBD had a melting temperature of 48.2 ± 0.08 
°C.12 These results show that agonists and the coactivator each serve to stabilize PXR-LBD. 
Ternary complexes of PXR-LBD and SRC-1 with either SR12813 or rifampicin were even 
more stable with melting temperatures of 52.5 ± 0.0512 and 52.6 ± 0.0355 °C, respectively. 
One might expect that this increase in stability upon addition of the third component would 
mean that the agonist and coactivator bind cooperatively, resulting in a ligand-dependent 
increase in affinity for the coactivator and vice versa. However, if the increased thermal 
stability is due to rifampicin and SRC-1 independently stabilizing different regions of PXR-
LBD, binding of one may not increase the receptor’s affinity for the other.
Another possibility is that ligand-dependent activation of PXR occurs through a novel 
pathway that is as yet uncharacterized. A recent study demonstrated that the nuclear receptor 
peroxisome proliferator-activated receptor-γ (PPARγ) is activated by structurally diverse 
serotonin and fatty acid metabolites.42 PPARγ, like PXR, has a flexible ligand binding 
pocket that can accommodate many different endogenous and exogenous ligands. Crystal 
structures of PPARγ in complex with a mimic of serotonin metabolites, indomethacin 
(IDM), showed that it bound in a distinct region of the ligand binding pocket and made 
direct contact with H12, securing the helix in the active conformation. However, fatty acid 
metabolites bound away from H12 and failed to make any contact with the helix. Surface 
plasmon resonance studies showed IDM induced PPARγ to recruit SRC-1. In fact, 
equilibrium dissociation constants of 34.2 and 0.96 μM were obtained for PPARγ and 
SRC-1 in the absence and presence of IDM, respectively. While IDM precipitated a 30-fold 
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increase in the affinity of PPARγ for SRC-1, the fatty acid metabolite, nitro-233, failed to 
enhance the interaction between the receptor and coactivator. Instead, it was proposed that 
nitro-233 may modulate heterodimerization with the retinoid X receptor. Given the 
structural diversity of PXR ligands, agonists like rifampicin may very well use different 
pathways to activate PXR.
Another aspect related to nuclear receptor function is the previous observation that many 
receptors have the capability of forming homodimers or heterodimers with other nuclear 
receptors. In the case of PXR, the physiologically relevant receptor dimer is thought to be 
one with RXR. Nonetheless, a previous work has shown that PXR-LBD homodimerizes in 
vitro with an equilibrium dissociation constant of 4.5 μM.26 A dimerization-null mutant was 
found to be incapable of binding the SRC-1 peptide either in the presence or in the absence 
of ligand. However, this result is not completely consistent with a separate report in which 
ligand-dependent interaction of the SRC-1 peptide with PXR-LBD was observed in vitro for 
a receptor concentration of 20 nM,43 well below the Kd for dimerization where one would 
predict that the PXR-LBD was present almost exclusively in monomeric form. One 
possibility is that the discrepancy arises in an indirect manner as a consequence of the 
mutations introduced to form the dimerization-null PXR-LBD. Regardless of these results, it 
is important to address the question of the state of dimerization of the PXR-LBD used in the 
work reported here. The solution concentration before application to the surface was 0.1 
mg/mL (2.6 μM); thus, the previously measured dimerization Kd would imply that the 
solutions contained primarily monomeric PXR-LBD with a non-negligible fraction of 
dimeric PXR-LBD. It is not possible to determine, after application to the surfaces and 
washing, what fraction of the immobilized PXR-LBD was in the monomeric or dimeric 
form. Nonetheless, the results show clearly that the SRC-1 peptide does specifically and 
reversibly interact with at least a fraction of the immobilized PXR-LBD. Definitive 
conclusions about the interaction of SRC-1 peptides with monomeric and dimeric forms of 
PXR-LBD await further measurements.
The interaction between corepressors and nuclear receptors, particularly PXR, has not been 
as extensively studied as that between coactivators and nuclear receptors. Cell-based assays 
have been used to show that the SMRT-RID specifically interacts with PXR while that of 
NCoR does not.13 Hence, our finding that the peptide derived from SMRT binds PXR-LBD 
with greater affinity (Kd′ ~70 μM) than the NCoR fragment (Kd′ ~170 μM) is consistent with 
what has been reported in the literature. Only one of two interaction domains 
(LXXXIXXXL; ID1 and ID2), ID2, in the SMRT-RID was shown to actually bind PXR.14 
In addition, of the two major SMRT splicing isoforms, α and τ, ID2 derived from SMRTα 
was found to bind preferentially to PXR.15 Compared to SMRTτ, SMRTα contains a 46-
amino acid insert immediately downstream of ID2. For the purposes of this study, a peptide 
containing ID2 from SMRTα was used. Reporter assays showed that SMRT (α and τ) 
reduces both the basal and rifampicin-induced transcriptional activity of PXR on the 
CYP3A4 promoter.13,14 These results indicate that SMRT is able to compete with 
coactivators to bind PXR in the absence and presence of ligand and thereby reduce the 
receptor’s transcriptional activity.
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In addition to the fact that SMRTα binds preferentially to PXR, it has been shown that 
SMRTα resists rifampicin-induced dissociation from PXR15 while SMRTτ does not.14 
These results are consistent with our observation that the corepressor peptide derived from 
SMRTα binds PXR-LBD with equal affinity in the presence and absence of rifampicin. 
However, the measured equilibrium dissociation constant of SMRTα (2337–2358) and 
PXR-LBD, which averages to ~70 μM over the three rifampicin concentrations (see Table 
2), is quite weak. In comparison, fluorescence polarization measurements of the thyroid 
hormone receptor-β LBD and SMRTα (2329–2358) yielded equilibrium dissociation 
constants of ~1 μM.16 It is unclear whether a larger fragment of SMRTα would have 
interacted with PXR-LBD with greater affinity. However, if the measured equilibrium 
constant is accurate, the interaction between SMRTα and PXR-LBD may not be 
physiologically relevant. It is possible that there are other corepressors that interact with 
PXR with a higher affinity and in a ligand-dependent manner.
Crystal structures of nuclear receptor LBDs and peptide fragments of SMRT have revealed 
the mode of corepressor binding and thereby elucidated the reason for the competition 
between corepressors and coactivators to bind nuclear receptors. A crystal structure of a 
PPAR isoform, PPARα, LBD in complex with an antagonist, GW490544, and the same 
peptide fragment of SMRTα (2337–2358) that was used in this work showed that the 
corepressor bound to a hydrophobic groove on the surface of the LBD that overlapped with 
the coactivator binding site.16 GW490544, like many nuclear receptor antagonists, had a 
portion that protruded out from the ligand binding pocket and prevented H12 (AF-2) from 
assuming its active conformation. This repositioning of H12 allowed the corepressor peptide 
to bind a groove formed by H3, H3′, H4, and H5. In the ternary complex, SMRT adopted a 
three-turn α-helix, unlike the two-turn α-helix formed by SRC-1. The additional helical turn 
in SMRT extended into the space that is normally occupied by H12 in the active 
conformation. The corepressor–PPARα complex was stabilized by polar contacts between 
the backbone carbonyls of A2348 and L2349 and the amine nitrogen of the same, conserved 
lysine residue in H3 that helps form the charge clamp with coactivators. Because the 
coactivator and corepressor binding sites overlap so greatly, one of these coregulators 
binding a nuclear receptor would necessarily prevent the other from binding. In the apo 
state, when H12 is allowed to freely sample active and inactive conformations, one would 
expect coactivators and corepressors to compete with each other to bind nuclear receptors. If 
in fact rifampicin fails to secure H12 in the active conformation, as is implied by existing 
structural data and our thermodynamic and kinetic data for SRC-1–PXR-LBD interactions, 
one would expect, as observed, that rifampicin does not affect the ability of corepressors to 
bind PXR-LBD.
Our thermodynamic and kinetic measurements indicate that rifampicin does not increase the 
affinity of PXR-LBD for the SRC-1 fragment or decrease the receptor’s affinity for SMRT. 
The vast structural diversity of PXR ligands makes it unlikely that all agonists would be able 
to form direct or indirect interactions with residues in H12, as seen with the π– cation 
interactions, to stabilize the active conformation. It is possible that the different PXR ligands 
work through an alternate mechanism, or even several mechanisms like in the case with 
PPARγ, to activate the receptor. One such possibility is that ligands, by filling the large 
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cavity that is the ligand binding pocket, confer stability to PXR and increase the receptor’s 
in vivo lifetime. Other plausible ligand-dependent regulatory mechanisms include an 
interplay between (physiologically relevant) corepressors and coactivators, 
homodimerization or heterodimerization with RXR, phosphorylation, and the differential 
affinity of PXR for various chaperone proteins in the ligand-bound versus apo states. These 
possible mechanisms of action are all avenues for future study.
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PXR pregnane X receptor
TIRFM total internal reflection fluorescence microscopy
SRC-1 steroid receptor coactivator-1
SMRT silencing mediator of retinoid and thyroid receptors
RXR retinoid X receptor
AF-2 activation function-2
LBD ligand binding domain




NCoR nuclear receptor corepressor
ER estrogen receptor
GR glucocorticoid receptor
PPAR peroxisome proliferator-activated receptor
GST glutathione S-transferase
RID receptor interaction domain
IDM indomethacin
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Specificity of PXR-LBD immobilization. The surface-associated fluorescence of F-PXR-
LBD bound to immobilized NeutrAvidin was measured, after surfaces had been treated in 
the presence (▼) and absence (●) of 100 μM D-biotin. The molar ratios of D-biotin to PXR-
LBD ranged from approximately 400 (0.01 mg/mL PXR-LBD) to 40 (0.1 mg/mL PXR-
LBD). Fluorescence was measured after incubation of F-PXR-LBD with surface-bound 
NeutrAvidin for 5 min and washing with 2 mL of buffer D. Mean values from three separate 
samples (obtained from eight points per sample) were averaged to generate the curves. 
Uncertainties are standard deviations associated with the 3-fold averages. All subsequent 
measurements were taken with 0.1 mg/mL PXR-LBD.
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Representative F-SRC-1–PXR-LBD binding isotherm. These plots, obtained from a single 
trial, show the surface-associated fluorescence of F-SRC-1 interacting with PXR-LBD in the 
presence of 1 μM rifampicin. (A) Representative values of F(+) (●) and F(−) (○). (B) 
Background-subtracted data, F(+) – F(−), curve-fit to the third expression in eq 1, which 
yields a Kd of 4.5 ± 1.4 μM, where the error is that associated with the fit. The PXR-LBD 
surface site density is (2.0 ± 0.2) × 103 molecules/μm2.
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Representative fluorescence recovery curves. These plots show typical fluorescence 
recovery curves for (A) 1.25 μM and (B) 20 μM F-SRC-1 interacting with PXR-LBD in the 
absence of ligand, obtained using a 300 mW, 50 ms bleach pulse. Fluorescence values have 
been normalized to average prebleach fluorescence values and then fit to one-exponential 
(green curves; f2 = 0 in eq 2) and two-exponential (red curves; f2 ≠ 0 in eq 2) models. It is 
evident, especially at the early recovery times, that the two-exponential model is a better fit 
for the data. All reported values are derived from two-exponential fits. For the curves shown 
here, the values of f1, k1, f2, k2, and μ were (A) 8.0 ± 0.4 kHz, 0.76 ± 0.08 s−1, 4.3 ± 0.4 kHz, 
0.126 ± 0.012 s−1, and 0.88, respectively, and (B) 15.0 ± 0.8 kHz, 1.56 ± 0.13 s−1, 2.5 ± 0.3 
kHz, 0.15 ± 0.02 s−1, and 0.83, respectively. The weighted average of the two rate constants, 
koff, was (A) 0.54 or (B) 1.36 s−1.
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F-SRC-1–PXR-LBD dissociation rate constants measured by TIR-FRAP and theoretical 
probabilities of rebinding. (A) Four to six recovery curves were measured for each of four (0 
μM rifampicin) or three (10 and 100 μM rifampicin) independently prepared samples, for 
each F-SRC-1 concentration. These measurements were taken using 300 mW, 50 ms; 200 
mW, 50 ms; and 100 mW, 100 ms bleach pulses. Each recovery curve was fit to eq 2, and 
the best-fit values of f1, k1, f2, and k2 were used to calculate koff according to eq 3. The off 
rates (koff) obtained from the recovery curves pertaining to a single sample were averaged. 
The points shown in the plot are the averages of three or four of these mean koff values for 
each F-SRC-1 and rifampicin concentration, with the associated standard deviation. These 
values of koff as a function of F-SRC-1 concentration, in the absence (○) and presence [10 
μM (●) or 100 μM (▼)] of rifampicin, were fit to the model in eq 5. The best-fit values of 
the intrinsic dissociation rates, , were 2.0 ± 0.1, 2.4 ± 0.3, and 2.4 ± 0.1 s−1 at 0, 10, and 
100 μM rifampicin, respectively. (B) Probabilities of rebinding computed by numerically 
integrating eq 6 from time zero (the center of the bleach pulse) to 30 s (after 
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photobleaching), using the following values: Kd = 4 μM, koff = 2 s−1, S = 3000 
molecules/μm2, D = 100 μm2/s, wx = 22.4 μm, and wy = 65.0 μm.
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Representative corepressor competition data. This plot shows the background-subtracted and 
normalized fluorescence as a function of SMRT (●) and NCoR (○) concentrations obtained 
at 5 μM F-SRC-1, in the absence of ligand. Background fluorescence, measured in the 
absence of surface-immobilized PXR-LBD, was subtracted, and the data were fit to eq 8 
with QS and Kd′ as free parameters and using the following fixed parameters: A = 5 μM, and 
Kd = 5 μM. Equilibrium dissociation constants of 65 ± 13 and 200 ± 50 μM were obtained 
for the SMRT–PXR-LBD (●) and NCoR–PXR-LBD (○) interactions, respectively. These 
data were normalized to fluorescence counts determined using the value of the fit parameter 
QS, A = 5 μM, Kd = 5 μM, and B = 0 μM (no corepressor). The data are averages of two 
trials, and the errors are the corresponding standard deviations.
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Table 1
F-SRC-1–PXR-LBD Equilibrium Dissociation Constants Measured by Steady-State TIRFMa
PXR-LBD [rifampicin] (μM) Kd (μM)
WT 0 4 ± 2
WT 0.1 5 ± 3
WT 1 4 ± 2
WT 10 5 ± 3
WT 100 4 ± 3
S247W/C284W 0 4 ± 2
WT & S247W/C284W (5 mM TCEP) 0 4 ± 2
WT (30% labeled F-SRC-1) 0 5 ± 2
a
Reported Kd values are averages of values obtained from two binding isotherms. Controls were conducted with a ligand-bound mimic of the 
receptor, PXR-LBD (S247W/C284W); 5 mM TCEP, as opposed to 2 mM; and F-SRC-1 with 30% labeling, instead of 10%. For the 5 mM TCEP 
control, one curve was measured for WT PXR-LBD and the other for the double tryptophan mutant. Uncertainties are propagated from the errors 
associated with each of the two fits. WT PXR-LBD refers to the AviTag-His6-PXR-LBD (130–434) fusion protein, with no other modifications.
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Table 2




0 65 ± 13 200 ± 50
10 82 ± 11 160 ± 40
100 51 ± 14 160 ± 40
a
Reported Kd′ values are averages obtained from two competition curves. Uncertainties are propagated from the errors associated with each of the 
two fits.
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